home / stock / zldaf / zldaf quote
Last: | $0.2328 |
---|---|
Change Percent: | 21.76% |
Open: | $0.23275 |
Close: | $0.1912 |
High: | $0.2328 |
Low: | $0.2328 |
Volume: | 1,000 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.2328 | $0.23275 | $0.1912 | $0.2328 | $0.2328 | 1,000 | 07-03-2024 |
$0.1912 | $0 | $0.1912 | $0 | $0 | 5 | 07-02-2024 |
$0.1912 | $0.1912 | $0.1912 | $0.1912 | $0.1912 | 3,749 | 06-25-2024 |
$0.29 | $0.29 | $0.29 | $0.29 | $0.29 | 148 | 06-11-2024 |
$0.30732 | $0 | $0.30732 | $0 | $0 | 28 | 06-05-2024 |
$0.30732 | $0.30732 | $0.30732 | $0.30732 | $0.30732 | 120 | 05-29-2024 |
$0.3 | $0 | $0.3 | $0 | $0 | 28 | 05-28-2024 |
$0.3 | $0.3 | $0.3 | $0.3 | $0.3 | 274 | 05-27-2024 |
$0.3 | $0.3 | $0.3 | $0.3 | $0.3 | 274 | 05-24-2024 |
$0.495 | $0 | $0.495 | $0 | $0 | 85 | 05-16-2024 |
$0.495 | $0.495 | $0.495 | $0.495 | $0.495 | 272 | 05-08-2024 |
$0.48 | $0 | $0.48 | $0 | $0 | 5 | 05-03-2024 |
$0.48 | $0 | $0.48 | $0 | $0 | 5 | 04-16-2024 |
$0.48 | $0 | $0.48 | $0 | $0 | 22 | 04-11-2024 |
$0.48 | $0 | $0.48 | $0 | $0 | 81 | 04-09-2024 |
$0.48 | $0.4743 | $0.48 | $0.48 | $0.4743 | 2,005 | 04-04-2024 |
$0.4704 | $0.4704 | $0.4704 | $0.4704 | $0.4704 | 114 | 04-03-2024 |
$0.5308 | $0 | $0.5308 | $0 | $0 | 5 | 04-02-2024 |
$0.5308 | $0 | $0.5308 | $0 | $0 | 57 | 03-28-2024 |
$0.5308 | $0 | $0.5308 | $0 | $0 | 8 | 03-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Zelda Therapeutics Ltd Company Name:
ZLDAF Stock Symbol:
OTCMKTS Market:
Zelda Therapeutics Ltd Website:
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) said that it has funding to conduct mid-to-late-stage FDA trials for its cannabinoid-based drug to treat autism spectrum disorder (ASD). The company received $8.6 million in funding from U.S.-based investment firm Cantheon Capital LLC to con...
Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets PR News...
Zelira Therapeutics Ltd (ASX: ZLD,OTC-QB: ZLDAF ), recieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market for its new insomnia medication Zenivol. Zenivol is the first clinically validated , pharmaceutic...